Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announces Date and Time for Third Quarter 2026 Earnings and Conference Call7.10.2026 22:05:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / October 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q3 2026 earnings before the market opens on Thursday, November 5, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loa
Surmodics Launches IOL Cartridge Coating Automation Center in Horsham7.10.2026 21:30:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 7, 2026 / Surmodics, a provider of surface technologies and performance coatings for the medical device industry, today announced at the opening of the American Academy of Ophthalmology annual meeting in New Orleans the launch of its IOL Cartridge Coating Automation Center at its Horsham, Pennsylvania site just outside Philadelphia. "The delivery system for an intraocular lens (IOL) combines precision injection-molded parts with a specifically selected lubricious, biofriendly coating," said Chip Hance, CEO of Surmodics. "As IOL manufacturers increasingly seek automated assembly and modern biomaterial formulations, our Automation Center provides automated coating processes designed for efficient production throughout the product lifecycle." The center brings together advanced hydrophilic coating technology, decades of IOL cartridge application expertise, precision coatings processes and automation capabilities in a manufacturing platform developed
Nevada Court Lifts Restriction, Clearing EESystem to Share Recording of November 2024 Meeting7.10.2026 15:00:00 CEST | Press release
LAS VEGAS, NV / ACCESS Newswire / October 7, 2026 / On September 25, 2026, Judge Erika Mendoza of the Eighth Judicial District Court of Nevada, Clark County, entered a written order denying Jason Shurka's motion for a preliminary injunction and granting Michael Bertolacini's motion to dissolve a temporary restraining order that had barred public dissemination of a recording of a November 14, 2024 meeting. The ruling was issued in Case No. A-25-910216-B, Department XXVII, a matter brought by Energy Enhancement System LLC ("EESystem"), Michael Bertolacini and Dr. Sandra Rose Michael against Jason Shurka and other defendants. In its written order, the court stated that its earlier suggestion that Jason Shurka's consent was needed to share the recording was incorrect, and that the restriction was dissolved as of the September 2, 2026 hearing. According to the order, the meeting was recorded on a cellphone by Manny Shurka, Jason Shurka's father, and Jason Shurka produced that recording in t
Steelcase 2025 Impact Report Highlights Progress in Reducing Emissions and Strengthening Communities7.10.2026 15:00:00 CEST | Press release
GRAND RAPIDS, MI / ACCESS Newswire / October 7, 2026 / Steelcase, a global design and thought leader in the world of work, today released its 2025 Impact Report, "Our Work Toward Better Futures." Steelcase recorded reductions in scope 1 and 2 emissions by 33% from its 2019 baseline and activated 324 Better Futures Community partnerships across 38 locations. The report details how Steelcase members, customers and partners are helping communities thrive and moving the organization closer to net zero. "Our commitments to people and the planet help focus the choices we make, the partnerships we build and the value we create," said Megan Blazina, senior vice president, international, digital and strategy at Steelcase, who also leads sustainability and social impact. "The progress in this report reflects how we're turning those commitments into action." As Steelcase looks ahead as a new part of HNI Corporation, the companies' shared focus on the wellbeing of people and the planet provides a
PostSig Expands Enterprise Platform for Financial and Operational Control7.10.2026 15:00:00 CEST | Press release
SAN FRANCISCO, CA / ACCESS Newswire / October 7, 2026 / PostSig today introduced a significant expansion of its enterprise platform, giving Finance, Procurement, Market Data and Operations teams a shared foundation for managing commercial performance. The expansion follows PostSig being named Best Data Governance Solution in WatersTechnology's 2026 Inside Market Data & Inside Reference Data Awards and its first enterprise deployment with data consultancy CJC, which manages market data for a London multi-asset broker. Pricing schedules, service orders, product inventories and entitlements change over time. When teams manage those records separately, they may see individual values but cannot reliably determine which one applies, why it changed, or how the change should affect spend. "Commercial commitments do not stop at the document," said Hendrik Bartel, CEO and Co-Founder of PostSig. "They show up in products, pricing, invoices, entitlements, usage, and accountability. PostSig connect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom